Research News
September 17, 2009
A large, multinational study to identify genetic risk factors associated with amyotrophic lateral sclerosis (ALS) has found two DNA sequences on chromosomes 9 and one on chromosome 19 that are
September 17, 2009
An experimental drug being developed to treat obesity and high blood lipid (fat) levels also may have promise for the treatment of Duchenne (DMD) and Becker (BMD) muscular dystrophies, according to
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/14%20LeadArt.jpg)
September 07, 2009
A study that analyzed medical records from four U.S. states has found that the average time between symptom onset and diagnosis of Duchenne muscular dystrophy (DMD) is 2.5 years, an interval that
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/11%20LeadArt.jpg)
August 28, 2009
Scentists at Oregon Health and Science University in Portland have developed an assisted-reproduction technique that has the potential to allow mothers with mitochondrial myopathies and other
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/13%20LeadArt.jpg)
August 27, 2009
Abnormal accumulation of a protein called "tau" has been considered by many to contribute to muscle degeneration in inclusion-body myositis (IBM). But recently, MDA grantee Steven Greenberg and
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/abnormal%20activationLeadArt.jpg)
August 27, 2009
An MDA-supported team of scientists in the United States and the Netherlands has uncovered new leads about the origins of facioscapulohumeral muscular dystrophy (FSHD), a disease whose biochemical
August 25, 2009
Abnormal accumulation of a protein called "tau" has been considered by many to contribute to muscle degeneration in inclusion-body myositis (IBM). But recently, MDA grantee Steven Greenberg and
August 25, 2009
An MDA-supported team of scientists in the United States and the Netherlands has uncovered new leads about the origins of facioscapulohumeral muscular dystrophy (FSHD), a disease whose biochemical
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/goldfish%2CLeadArt.jpg)
August 25, 2009
Stepped-up production of fragments of acetylcholine receptors, the microscopic "landing pads" on muscle fibers that normally help process signals from the nervous system, may provoke the immune
August 20, 2009
Stepped-up production of fragments of acetylcholine receptors, the microscopic "landing pads" on muscle fibers that normally help process signals from the nervous system, may provoke the immune
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/lab-mouseLeadArt.jpg)
August 17, 2009
A protein known as insulin-like growth factor 1 (IGF1) may provide a new lead in the treatment of spinal-bulbar muscular atrophy (SBMA), also known as Kennedy disease.
A multinational team
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/laugh%20cry%20masks%20LeadArt.jpg)
August 16, 2009
The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/TangledLeadArt_0.jpg)
August 16, 2009
A new forum for easily accessible scientific information on alternative and off-label (not approved by the Food and Drug Administration) treatments for ALS is now being offered by the World
August 16, 2009
A new forum for easily accessible scientific information on alternative and off-label (not approved by the Food and Drug Administration) treatments for ALS is now being offered by the World
August 16, 2009
The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/family%20conferenceLeadArt.jpg)
August 13, 2009
A conference for families affected by congenital muscular dystrophy (CMD) is taking place Saturday and Sunday, Aug. 15-16, 2009, at Children's Hospital of Philadelphia, under the sponsorship of Cure
August 13, 2009
The pharamaceutical company Avanir has announced positive results for its phase 3 trial to treat unwanted episodes of laughing and crying in patients with ALS and multiple sclerosis using its
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/MaskLeadArt.jpg)
July 31, 2009
Scientists at three U.S. institutions have used a very small synthetic molecule to correct the genetic defect in cells taken from a person with spinal muscular atrophy (SMA), a disease in which
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/beakers%20silhouetteLeadArt_0.jpg)
July 30, 2009
The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the
July 30, 2009
The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/als%20tdi%20Lead%20Art.jpg)
July 29, 2009
On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/Vitamin%20CLeadArt.jpg)
July 29, 2009
A recent trial has shown inconclusive results from various doses of vitamin C (ascorbic acid) in patients with the peripheral nerve disease type 1A Charcot-Marie-Tooth disease (CMT1A), and the jury
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/als%20tdi%200169%20LeadArt_0.jpg)
July 29, 2009
On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who
July 27, 2009
The Richmond, Va., biopharmaceutical company Insmed announced July 27, 2009, that it will not supply its experimental drug Iplex to any new patients with amyotrophic lateral sclerosis (ALS) for the
July 27, 2009
On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who
Pages
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc. All rights reserved.
